SCHEMBL8768945

SCHEMBL8768945

CN(C)c1ccc(C(=O)N/N=C/c2cncc(/C=N/NC(=O)c3ccc(N(C)C)cc3)c2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 1/20 0.70
HDAC8 Q9BY41 2/20 0.67
HDAC6 Q9UBN7 2/20 0.67
ESRRG P62508 1/20 0.67
MAPT P10636 7/20 0.66
KMT2A Q03164 5/20 0.66
ALDH1A1 P00352 4/20 0.66
KDM4E B2RXH2 4/20 0.66
RAB9A P51151 5/20 0.65
NPC1 O15118 4/20 0.65
PKM P14618 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
POLB P06746 1/20 0.60
MEN1 O00255 2/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
GFER P55789 2/20 0.57
LMNA P02545 1/20 0.55
MCL1 Q07820 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8769635 0.87 HDAC8 (0.72) MPOHDAC8HDAC6ESRRGMAPT
SCHEMBL12791111 0.86 HDAC8 (0.81) MPOHDAC8HDAC6ESRRGMAPT
SCHEMBL8768051 0.83 HDAC8 (0.66) MPOHDAC8HDAC6ESRRGMAPT
N'-(4-Dimethylaminobenzylidene)Isonicotinohydrazide SCHEMBL9755103 0.82 MPO (1.00) MPOHDAC8HDAC6ESRRGMAPT
N'-(4-Dimethylaminobenzylidene)Isonicotinohydrazide SCHEMBL11774611 0.82 MPO (1.00) MPOHDAC8HDAC6ESRRGMAPT
SCHEMBL21531471 0.82 MAPT (0.89) MPOHDAC8HDAC6ESRRGMAPT
SCHEMBL20328281 0.82 MAPT (0.89) MPOHDAC8HDAC6ESRRGMAPT
SCHEMBL8768655 0.82 HDAC8 (0.64) MPOHDAC8HDAC6ESRRGMAPT
SCHEMBL12937892 0.81 HDAC8 (0.77) MPOHDAC8HDAC6ESRRGMAPT
SCHEMBL25424218 0.81 MAPT (0.82) MPOHDAC8HDAC6ESRRGMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
WO-2012068406-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-05-24 WO disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL MPO 2031/4885HDAC8 3359/4885HDAC6 3930/4885
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF MPO 1780/4885HDAC8 1812/4885HDAC6 3025/4885
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF MPO 1780/4885HDAC8 1812/4885HDAC6 3025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.